PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30987932-8 2019 Testosterone also regulates the expression of phosphodiesterase type 5. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 46-70 11045039-7 2000 In an animal experiment, the intracavernous pressure, the density of alpha-receptors, and the PDE5 activity depended on normal testosterone levels. Testosterone 127-139 phosphodiesterase 5A Homo sapiens 94-98 33420743-8 2021 There was a strong univariant relation (r=0.95, p<0.001) between PDE5-I prescribing and testosterone prescribing. Testosterone 88-100 phosphodiesterase 5A Homo sapiens 65-69 34875337-2 2022 Although they have high specificity for PDE5, these inhibitors are suspected to cross-interact also with cyclic adenosine monophosphate (cAMP)-specific PDEs, inducing the intracellular accumulation of this cyclic nucleotide and related testosterone increase, positively impacting male reproductive parameters. Testosterone 236-248 phosphodiesterase 5A Homo sapiens 40-44 32420164-1 2020 Background: Combining testosterone and phosphodiesterase 5 inhibitors (PDE5-Is) has become increasingly common in the treatment of men with erectile dysfunction (ED) and low testosterone levels, but combination therapy involving PDE5-Is and testosterone is highly debated, with strong reasons for and against argued by the various opinion leaders. Testosterone 22-34 phosphodiesterase 5A Homo sapiens 71-75 32420164-1 2020 Background: Combining testosterone and phosphodiesterase 5 inhibitors (PDE5-Is) has become increasingly common in the treatment of men with erectile dysfunction (ED) and low testosterone levels, but combination therapy involving PDE5-Is and testosterone is highly debated, with strong reasons for and against argued by the various opinion leaders. Testosterone 174-186 phosphodiesterase 5A Homo sapiens 71-75 32420164-1 2020 Background: Combining testosterone and phosphodiesterase 5 inhibitors (PDE5-Is) has become increasingly common in the treatment of men with erectile dysfunction (ED) and low testosterone levels, but combination therapy involving PDE5-Is and testosterone is highly debated, with strong reasons for and against argued by the various opinion leaders. Testosterone 174-186 phosphodiesterase 5A Homo sapiens 71-75 32420164-2 2020 PDE5-Is can be given prior to, alongside or after the commencement of any testosterone replacement therapy. Testosterone 74-86 phosphodiesterase 5A Homo sapiens 0-4 32420164-3 2020 Meanwhile, combination of PDE5-Is and testosterone is reported to better increase testosterone levels and thus improve International Index of Erectile Function (IIEF) score in hypogonadal men. Testosterone 82-94 phosphodiesterase 5A Homo sapiens 26-30 32420164-4 2020 The objective of this meta-analysis was to assess whether testosterone therapy (TTh) can possibly enhance the reaction to PDE5-Is in men with ED and hypogonadism. Testosterone 58-70 phosphodiesterase 5A Homo sapiens 122-126 29145710-8 2018 Testosterone treatment reduced (p < 0.05) prolonged detumescence in Sickle mice and normalized downregulated P-PDE5 (Ser-92), PDE5, P-eNOS (Ser-1177), and P-Akt (Ser-473) protein expressions in the Sickle mouse penis. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 114-118 22971615-0 2013 Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. Testosterone 23-35 phosphodiesterase 5A Homo sapiens 63-67 25643866-0 2015 Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients? Testosterone 5-17 phosphodiesterase 5A Homo sapiens 43-47 24350081-5 2013 Testosterone has been shown to increase the expression of PDE-5. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 58-63 24350081-7 2013 In view of the complexity of ED, as well as the effect of testosterone on erection, it is concluded that PDE-5 inhibitors in combination with testosterone replacement would be a better therapy alternative in the management of erectile dysfunction in hypogonadal patients. Testosterone 58-70 phosphodiesterase 5A Homo sapiens 105-110 23892217-6 2013 Hypogonadal patients in whom PDE5 inhibitor failed could be rescued by the administration of testosterone. Testosterone 93-105 phosphodiesterase 5A Homo sapiens 29-33 29145710-10 2018 In conclusion, in the mouse model of human SCD, increasing testosterone to eugonadal levels reduced priapic activity and reversed impaired Akt/eNOS activity and PDE5 protein expression in the penis. Testosterone 59-71 phosphodiesterase 5A Homo sapiens 161-165 29256125-7 2017 Some PDE5 inhibitors tend to increase circulating testosterone levels somewhat. Testosterone 50-62 phosphodiesterase 5A Homo sapiens 5-9 23312193-0 2013 Re: combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-responders with severe and intermediate testosterone deficiency. Testosterone 27-39 phosphodiesterase 5A Homo sapiens 67-71 22971615-0 2013 Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. Testosterone 121-133 phosphodiesterase 5A Homo sapiens 63-67 22971615-1 2013 Several studies have suggested combination therapy with testosterone supplementation in patients not responding to PDE5 inhibitors. Testosterone 56-68 phosphodiesterase 5A Homo sapiens 115-119 23343170-7 2013 Level 1 evidence also exists that treatment of hypogonadism with total testosterone < 300 ng/dL (10.4 nmol/L) can either improve ED or add to the efficacy of PDE5 inhibitors. Testosterone 71-83 phosphodiesterase 5A Homo sapiens 161-165 21789066-3 2009 Testosterone (T) is an important player in the regulation of vascular tone through non-genomic actions exerted via blockade of extracellular-calcium entry or activation of potassium channels; also, adequate T concentrations are paramount for the regulation of phosphodiesterase type-5 (PDE5) expression and finally, for the actions exerted by hydrogen sulphide, a gas involved in the alternative pathway controlling vasodilator responses in penile tissue. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 260-284 22028410-0 2012 Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 91-95 20704642-1 2011 INTRODUCTION: Addition of testosterone (T) may improve the action of phosphodiesterase type 5 inhibitors (PDE5-Is) in patients with erectile dysfunction not responding to PDE5-Is with low or low-normal T levels. Testosterone 26-38 phosphodiesterase 5A Homo sapiens 106-110 21045249-8 2010 Combined treatment with testosterone plus phosphodiesterase 5 (PDE 5)seems to be an adequate alternative to rescue patients with erectile dysfunction and hypogonadism not responding to monotherapy, be it with testosterone alone or PDE 5 inhibitors alone. Testosterone 24-36 phosphodiesterase 5A Homo sapiens 231-236 21045249-8 2010 Combined treatment with testosterone plus phosphodiesterase 5 (PDE 5)seems to be an adequate alternative to rescue patients with erectile dysfunction and hypogonadism not responding to monotherapy, be it with testosterone alone or PDE 5 inhibitors alone. Testosterone 209-221 phosphodiesterase 5A Homo sapiens 63-68 21045249-10 2010 Moreover, testosterone substitution therapy may improve the other symptoms of TDS and increase the efficacy of PDE5 inhibitors when they are not effective in monotherapy. Testosterone 10-22 phosphodiesterase 5A Homo sapiens 111-115 20057984-9 2010 Particularly testosterone might be a helpful supportive therapy in cases where PDE-5 antagonists have tended to lose their effectiveness on the erectile tissue in the treatment of ED. Testosterone 13-25 phosphodiesterase 5A Homo sapiens 79-84 19732305-0 2009 Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 84-88 21834870-1 2011 INTRODUCTION: Up to 30% of erectile dysfunction (ED) patients treated with phosphodiesterase type 5 (PDE5) inhibitors do not show improved sexual function, which may be due in part to low serum testosterone. Testosterone 194-206 phosphodiesterase 5A Homo sapiens 75-99 21834870-1 2011 INTRODUCTION: Up to 30% of erectile dysfunction (ED) patients treated with phosphodiesterase type 5 (PDE5) inhibitors do not show improved sexual function, which may be due in part to low serum testosterone. Testosterone 194-206 phosphodiesterase 5A Homo sapiens 101-105 21834870-4 2011 AIM: To determine if 12-month treatment with a testosterone gel improves sexual function in hypogonadal men, as measured by the Brief Male Sexual Function Inventory (BMSFI), and in subgroups defined by low testosterone, PDE5 inhibitor use, and prior TRT. Testosterone 47-59 phosphodiesterase 5A Homo sapiens 220-224 20584218-12 2010 * Testosterone replacement therapy may lead to symptomatic improvement (improved wellbeing) and enhance the effectiveness of PDE5 inhibitors (Level 1, Grade A). Testosterone 2-14 phosphodiesterase 5A Homo sapiens 125-129 21789066-3 2009 Testosterone (T) is an important player in the regulation of vascular tone through non-genomic actions exerted via blockade of extracellular-calcium entry or activation of potassium channels; also, adequate T concentrations are paramount for the regulation of phosphodiesterase type-5 (PDE5) expression and finally, for the actions exerted by hydrogen sulphide, a gas involved in the alternative pathway controlling vasodilator responses in penile tissue. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 286-290 16760638-6 2005 Finally, considering that androgens may influence sexual behavior by modifying the central nervous system neurotransmitter targeted system, the potentiation of PDE5 inhibitors with testosterone supplementation may be considered to improve erectile function and quality of life in older males. Testosterone 181-193 phosphodiesterase 5A Homo sapiens 160-164 19207276-2 2009 Activation of central mechanisms may open a window for phosphodiesterase type 5 inhibitors (PDE5) to be effective; as a consequence, the combination of testosterone and a PDE5 inhibitor will restore sexual function. Testosterone 152-164 phosphodiesterase 5A Homo sapiens 92-96 19138366-2 2009 A single dose of testosterone might induce an increase in sensitivity for sexual stimuli, which in turn allows a PDE5 inhibitor to be effective in boosting the physiological sexual response. Testosterone 17-29 phosphodiesterase 5A Homo sapiens 113-117 16651047-10 2006 Testosterone treatment may ameliorate the response to the phosphodiesterase 5 (PDE5) inhibitors in hypogonadal men and men with low-normal serum testosterone. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 58-77 16651047-10 2006 Testosterone treatment may ameliorate the response to the phosphodiesterase 5 (PDE5) inhibitors in hypogonadal men and men with low-normal serum testosterone. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 79-83 16651047-10 2006 Testosterone treatment may ameliorate the response to the phosphodiesterase 5 (PDE5) inhibitors in hypogonadal men and men with low-normal serum testosterone. Testosterone 145-157 phosphodiesterase 5A Homo sapiens 58-77 16651047-10 2006 Testosterone treatment may ameliorate the response to the phosphodiesterase 5 (PDE5) inhibitors in hypogonadal men and men with low-normal serum testosterone. Testosterone 145-157 phosphodiesterase 5A Homo sapiens 79-83 16422803-15 2005 The combination of testosterone plus PDE5 inhibitors may be considered for the treatment of ED in men with low to low-normal testosterone levels, who had inadequate response to prior treatment with PDE5 inhibitors alone. Testosterone 125-137 phosphodiesterase 5A Homo sapiens 37-41 15822384-6 2005 With these patients, the prescription of testosterone replacement therapy may improve the response of PDE5 inhibitors. Testosterone 41-53 phosphodiesterase 5A Homo sapiens 102-106 19400854-8 2009 The results suggest positive effects of addition of testosterone to treatment with PDE-5 inhibitors in hypogonadal men with OSAS, which should be confirmed in larger controlled studies. Testosterone 52-64 phosphodiesterase 5A Homo sapiens 83-88 19011292-8 2009 A significant proportion of men who fail to respond to a PDE5 inhibitor are testosterone deficient. Testosterone 76-88 phosphodiesterase 5A Homo sapiens 57-61 18305486-7 2008 However, testosterone may ameliorate the expression of the phosphodiesterase-5 (PDE5) inhibitor, and the use of testosterone in conjunction with the PDE5 inhibitor revealed convincing results. Testosterone 9-21 phosphodiesterase 5A Homo sapiens 59-78 18305486-7 2008 However, testosterone may ameliorate the expression of the phosphodiesterase-5 (PDE5) inhibitor, and the use of testosterone in conjunction with the PDE5 inhibitor revealed convincing results. Testosterone 9-21 phosphodiesterase 5A Homo sapiens 80-84 16979814-2 2006 OBJECTIVES: To review molecular mechanisms underlying androgen action upon its receptor and phosphodiesterase type 5 (PDE5) expression and regulation by testosterone in cavernous tissue and their clinical implication in the treatment of ED refractory to PDE5 inhibitors (PDE5-Is). Testosterone 153-165 phosphodiesterase 5A Homo sapiens 92-116 16979814-2 2006 OBJECTIVES: To review molecular mechanisms underlying androgen action upon its receptor and phosphodiesterase type 5 (PDE5) expression and regulation by testosterone in cavernous tissue and their clinical implication in the treatment of ED refractory to PDE5 inhibitors (PDE5-Is). Testosterone 153-165 phosphodiesterase 5A Homo sapiens 118-122 16979814-2 2006 OBJECTIVES: To review molecular mechanisms underlying androgen action upon its receptor and phosphodiesterase type 5 (PDE5) expression and regulation by testosterone in cavernous tissue and their clinical implication in the treatment of ED refractory to PDE5 inhibitors (PDE5-Is). Testosterone 153-165 phosphodiesterase 5A Homo sapiens 254-258 16979814-2 2006 OBJECTIVES: To review molecular mechanisms underlying androgen action upon its receptor and phosphodiesterase type 5 (PDE5) expression and regulation by testosterone in cavernous tissue and their clinical implication in the treatment of ED refractory to PDE5 inhibitors (PDE5-Is). Testosterone 153-165 phosphodiesterase 5A Homo sapiens 254-258 16979814-5 2006 Orally effective PDE5-Is, such as sildenafil, tadalafil, or vardenafil, may be ineffective depending on the demonstration of testosterone regulation of PDE5 expression in human corpus cavernous, and their efficacy may be enhanced by testosterone adjunction whenever necessary. Testosterone 125-137 phosphodiesterase 5A Homo sapiens 152-156 16979814-5 2006 Orally effective PDE5-Is, such as sildenafil, tadalafil, or vardenafil, may be ineffective depending on the demonstration of testosterone regulation of PDE5 expression in human corpus cavernous, and their efficacy may be enhanced by testosterone adjunction whenever necessary. Testosterone 233-245 phosphodiesterase 5A Homo sapiens 17-21 16979814-7 2006 Identification of threshold values for testosterone supplementation to appropriately benefit from PDE5-Is failure may improve clinical management of unresponsive patients with minimization of unwanted effects. Testosterone 39-51 phosphodiesterase 5A Homo sapiens 98-102 16939550-5 2006 A number of laboratory and human studies have shown the combination of testosterone and other ED treatments, such as phosphodiesterase type 5 (PDE5) inhibitors, to be beneficial in patients with ED and hypogonadism, who fail PDE5 inhibitor therapy alone. Testosterone 71-83 phosphodiesterase 5A Homo sapiens 117-141 16939550-5 2006 A number of laboratory and human studies have shown the combination of testosterone and other ED treatments, such as phosphodiesterase type 5 (PDE5) inhibitors, to be beneficial in patients with ED and hypogonadism, who fail PDE5 inhibitor therapy alone. Testosterone 71-83 phosphodiesterase 5A Homo sapiens 143-147 16939550-5 2006 A number of laboratory and human studies have shown the combination of testosterone and other ED treatments, such as phosphodiesterase type 5 (PDE5) inhibitors, to be beneficial in patients with ED and hypogonadism, who fail PDE5 inhibitor therapy alone. Testosterone 71-83 phosphodiesterase 5A Homo sapiens 225-229 16939550-7 2006 Testosterone replacement therapy has potentially evolved from a monotherapy for ED in cases of low testosterone, to a combination therapy with PDE5 inhibitors. Testosterone 0-12 phosphodiesterase 5A Homo sapiens 143-147 16611151-12 2006 Adding an androgen to a PDE5 inhibitor may help when circulatory testosterone levels are low. Testosterone 65-77 phosphodiesterase 5A Homo sapiens 24-28 16372114-8 2006 (2) Several studies have indicated that PDE5 inhibitors are not always sufficient to restore erectile potency in men, and that testosterone improves the therapeutical response to PDE5 inhibitors considerably. Testosterone 127-139 phosphodiesterase 5A Homo sapiens 179-183 14764637-4 2004 In this model, hypogonadism reduced, and testosterone (T) supplementation restored, CC PDE5 gene and protein expression. Testosterone 41-53 phosphodiesterase 5A Homo sapiens 87-91